Physician profile
Baoen Jiang
NPI 1528140597
$51,716.24
in general payments reported to CMS, 2019-2025
66 companies · $3,803 in 2025
The $3,803 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,721 · 2021: $12K · 2022: $6,124 · 2023: $4,793 · 2024: $4,915 · 2025: $3,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,372.75 |
| Education | $138.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21,514.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,873.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $3,324.72 | 2019-2025 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,340.42 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $2,086.98 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Amgen INC. | $2,079.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $1,374.51 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $1,372.15 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,254.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $1,178.93 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $811.16 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $741.15 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.93 | 2019-2024 | Trulance, Xifaxan |
| Pfizer INC. | $616.16 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $511.89 | 2019-2024 | Xarelto |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baoen Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.